Abstract P1-05-20: Validation of the HER2 Activation Response Predictive Signature (HARPS) as a Predictive Biomarker for HER2+ Therapy Response in the Neoadjuvant SettingEmanuel Petricoin, Shridar Ganesan, Rosa I. Gallagher et al.|Clinical Cancer Research|2025Cited by 0